Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Management of Chronic Kidney Disease Stages 1–3

Slide: 19 of 29

Clinical Bottom Line: Risk for Mortality in Patients With CKD Stages 1–3 Treated With Beta-Blockers

Beta-blocker treatment versus placebo reduced the risk for all-cause mortality by 31 percent in patients with congestive heart failure and impaired eGFR, most of whom already were treated with an ACEI or an ARB (low strength of evidence). Patients with systolic congestive heart failure may already have an indication for beta-blockers, regardless of whether they have CKD.

Abbreviations:
95% CI = 95-percent confidence interval; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; ARR = absolute risk reduction; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; RR = risk ratio